Cureus
October 1, 2022
Dev B Goel, Sarju Zilate
24 citations
Psilocybin is a plant alkaloid that is derived from precursors of tryptamine and is present in many different types of mushrooms. It has been utilized by indigenous peoples of Central and South America for centuries in a ceremonial setting to promote spiritual experiences. Indigenous societies have long employed psilocybin and other 5-HT 2A agonist classic psychedelics in their rites. They were...
Anthropology of Consciousness
September 26, 2022
Owain J. Graham, Gary Rojas Saucedo, Matteo Politi
11 citations
Abstract Research on psychedelic‐assisted psychotherapy has shown that music affects therapeutic outcomes at a fundamental level. The development of such therapies calls for research on the use of music with consciousness‐altering substances, especially in contexts informed by their traditional use. Informed by ethnographic reports, our project answers this call, investigating the phenomenology...
Christian bioethics Non-Ecumenical Studies in Medical Morality
September 19, 2022
Bryan Mccarthy
12 citations
Abstract In recent years, researchers in the “psychedelic renaissance” have been reinvestigating the therapeutic potential of psychedelic compounds for conditions like post-traumatic stress disorder, clinical anxiety/depression, and addiction. Each of these has treatment-resistant cases, sometimes decades in the making, but studies employing psychedelics to address them are yielding impressive...
Addiction Science & Clinical Practice
September 16, 2022
Vanessa C Somohano, Josh Kaplan, Aurora G Newman et al.
Women with co-occurring posttraumatic stress disorder (PTSD) and substance use disorder (SUD) experience systemic barriers that place them in danger of poorer treatment outcomes. Some mindfulness-based interventions (MBIs) have demonstrated efficacy in reducing PTSD and SUD symptoms. Mindfulness practice is a core component of MBIs, thought to elicit and maintain positive behavioral change;...
Health Psychology Research
September 15, 2022
Danyon J Anderson, Jessica Zhou, David Cao et al.
Ketamine is a common medical anesthetic and analgesic but is becoming more widely used as a recreational drug. Significant side effects on the urinary tract are associated with frequent recreational ketamine use most notably ketamine-induced cystitis (KIC). Regular ketamine consumption has been shown to increase the risk of cystitis symptoms by 3- to 4-fold, and cessation of ketamine use is...
Mindfulness
September 15, 2022
Anna Parisi, R Lynae Roberts, Adam W. Hanley et al.
Objectives: Mindfulness-Oriented Recovery Enhancement (MORE) is an integrative intervention designed to ameliorate addiction, chronic pain, and psychiatric symptoms. Although multiple randomized controlled trials (RCTs) have examined the clinical efficacy of MORE, no study has quantitatively synthesized this body of research. Thus, we conducted a meta-analysis of RCTs examining the effects of...
September 8, 2022
Adam Safron, Matthew Johnson
5 citations
preprint
Here we consider psychedelics with respect to their mechanisms of action, use, and implications for our understandings of brain and mind. This review is somewhat nontraditional in its scope, with discussions of both basic facts as well as theoretical speculations. We chose this approach given the unique historical context we find ourselves in at present. While we have decades of investigations...
bioRxiv Preprint Server
September 6, 2022
Tommaso Di Ianni, Matine M. Azadian, Sedona N. Ewbank et al.
2 citations
preprint
Subanesthetic ketamine rapidly and robustly reduces depressive symptoms in patients with treatment-resistant depression. While it is commonly classified as an N-methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of ketamine in depression may...
Drugs Education Prevention and Policy
September 4, 2022
Jason B. Luoma, Brian Pilecki, Alan K. Davis et al.
13 citations
As evidence for psychedelic-assisted therapy accumulates, legalization becomes more likely. As a result, there is an increasing need for psychologists to become educated about psychedelics and their therapeutic effects as they will play an important role in disseminating this treatment. Therefore, understanding psychologists’ current attitudes toward psychedelics is integral in informing...
Addiction Science & Clinical Practice
September 4, 2022
Lukas Andreas Basedow, Melina Felicitas Wiedmann, Veit Roessner et al.
17 citations
Abstract Background Post-traumatic stress disorder (PTSD) and substance use disorders (SUDs) often co-occur in adolescent patients. Previous research has shown that these patients differ from SUD patients without PTSD in terms of their substance use patterns. In this study, we aimed to test whether substance use in this population is related to an attempt to self-medicate PTSD-related symptoms....
Contemporary Clinical Trials
September 2022
David S Black, Matthew G. Kirkpatrick
A majority of the 34 million people who currently smoke cigarettes report wanting to quit smoking yet most attempts to quit end in relapse. A mindfulness based intervention (MBI) is an intervention package used to reinforce an individual's practice of mindfulness meditation in daily life. MBIs delivered by phone app offer daily prompts to guide bouts of mindfulness meditation, that is,...
The Lancet Psychiatry
September 2022
Kat Petrilli, Shelan Ofori, Lindsey A. Hines et al.
Cannabis potency, defined as the concentration of Δ9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes for cannabis users. We present, to our knowledge, the first systematic review of the association of cannabis potency with mental health and addiction (PROSPERO, CRD42021226447). We searched Embase, PsycINFO, and MEDLINE (from...
Experimental and Clinical Psychopharmacology
September 1, 2022
Julie A E Christensen, David C. Fipps, J Michael Bostwick
4 citations
Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis,...
Psychiatric Annals
September 1, 2022
Brian S. Barnett, Jeremy Weleff
6 citations
Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin may hold treatment potential for alcohol, opioid, tobacco, and other substance use disorders (SUDs). The mechanisms by which psychedelics might exert therapeutic efficacy in these conditions have not been fully...
Addiction Biology
August 31, 2022
Elena Giné, Javier Calleja‐conde, José Á. Morales-García et al.
49 citations
Abstract Classic psychedelics refer to substances such as lysergic acid diethylamide (LSD), psilocybin, ayahuasca, and mescaline, which induce altered states of consciousness by acting mainly on 5‐HT 2A receptors. Recently, the interest of psychedelics as pharmacological treatment for psychiatric disorders has increased significantly, including their use on problematic use of alcohol. This...
Cureus
August 25, 2022
Vedant N Hedau, Ashish P Anjankar
5 citations
Psychedelics are hallucinogenic drugs that alter the state of consciousness substantially. They bring about psychological, auditory, and visual changes. The psychedelics act on the brain, implying that they have a powerful psychological impact. One of the main factors contributing to disability worldwide is pain. The majority of people deal with pain on a daily basis. Living with chronic pain...
JAMA Psychiatry
August 24, 2022
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al.
668 citations
Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. Objective To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and...
Neuropsychopharmacology
August 22, 2022
Yanning Zuo, Attilio Iemolo, Patricia Montilla‐Perez et al.
24 citations
During adolescence, frequent and heavy cannabis use can lead to serious adverse health effects and cannabis use disorder (CUD). Rodent models of adolescent exposure to the main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), mimic the behavioral alterations observed in adolescent users. However, the underlying molecular mechanisms remain largely unknown. Here, we treated...
Drug and Alcohol Dependence
August 19, 2022
Nicolas Garel, Christina Mcanulty, Kyle T. Greenway et al.
33 citations
BACKGROUND: Alcohol use disorder is highly prevalent and has important economical, societal, psychiatric, and medical consequences. All currently approved therapeutic approaches targeting alcohol dependence have relatively modest effects and high relapse rates. Recent evidence suggests that ketamine may be an effective intervention to treat alcohol use disorder and alcoholic withdrawal. This...
Current Addiction Reports
August 15, 2022
Bradford Martins, Will Rutland, Joao P De Aquino et al.
Purpose of review: This review summarizes recent clinical trial research on pharmacological treatments for substance use disorders, with a specific focus on agents with potential abuse liability. Recent findings: Pharmacological treatments for substance use disorders may include gabapentinoids, baclofen, modafinil, ketamine, cannabinoids, gamma-hydroxybutyrate, and psychedelics. Gabapentinoids...